BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37439706.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1389.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CD49d, the alpha chain of the very late antigen-4 (VLA-4) integrin, has a negative prognostic impact in chronic lymphocytic leukemia treated with the Bruton's tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib. Despite BTK inhibition, VLA-4 remains inside-out activated via B-cell receptor, an activation dampened by phosphoinositide 3-kinase inhibitors. Evaluation of CD49d expression in patients starting BTK inhibitor therapy may improve their prognostic stratification. See related article by Alsadhan et al., p. 3612.
Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell